Repatha and Finasteride Interaction: What Women Need to Know

The Short Answer: Is There a Repatha-Finasteride Interaction?

No clinically meaningful pharmacokinetic interaction exists between Repatha (evolocumab) and finasteride. Evolocumab is a fully human monoclonal antibody that is broken down by normal protein catabolism throughout the body. It does not pass through the liver's cytochrome P450 enzyme system, does not bind P-glycoprotein transporters, and does not alter plasma protein binding in ways that would affect finasteride levels.

Finasteride, by contrast, is a small-molecule 5-alpha reductase inhibitor metabolized primarily by CYP3A4 in the liver, with minor contributions from CYP1A2. Because evolocumab never touches those pathways, the two drugs simply do not interfere with each other's pharmacokinetics.

That does not mean the combination is without complexity. Both drugs carry distinct safety signals for women, and the androgen biology that finasteride targets overlaps in meaningful ways with cardiometabolic health. The rest of this article walks through the mechanism in detail, what changes by life stage, and when to get a clinician involved.

How Evolocumab Works: Why CYP Interactions Don't Apply

The PCSK9 mechanism

Evolocumab binds and inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that normally marks LDL receptors on liver cells for degradation. By blocking PCSK9, evolocumab allows more LDL receptors to remain on the hepatocyte surface, pulling more LDL-cholesterol out of the bloodstream. In the FOURIER trial (n = 27,564 patients with established ASCVD), evolocumab reduced LDL-C by 59% versus placebo and cut the risk of major adverse cardiovascular events by 15% over a median follow-up of 2.2 years.

Why monoclonal antibodies don't use CYP enzymes

Small-molecule drugs reach the liver in high concentrations after oral absorption and compete for cytochrome P450 enzymes. Monoclonal antibodies like evolocumab are too large to be filtered by the kidney and are instead catabolized by endosomes in cells throughout the body into individual amino acids. The FDA prescribing label for evolocumab explicitly states that no formal drug-drug interaction studies were needed because the molecule is not metabolized by CYP enzymes, is not a P-glycoprotein substrate, and does not inhibit or induce CYP isoforms.

This is a clean architectural separation. Drugs that interact with CYP3A4 (statins, azole antifungals, some hormonal contraceptives) can raise or lower finasteride exposure. Evolocumab cannot.

How Finasteride Works: The 5-Alpha Reductase Pathway

Finasteride competitively inhibits 5-alpha reductase (5-AR) type II (and at higher doses, type I), the enzyme that converts testosterone to dihydrotestosterone (DHT). DHT is the androgen responsible for androgenic alopecia (female pattern hair loss), and it plays a role in the excess androgen activity seen in polycystic ovary syndrome (PCOS).

At the 1 mg dose, finasteride reduces scalp DHT by approximately 64% and serum DHT by roughly 68% in women. At the 5 mg dose used in benign prostatic hyperplasia, serum DHT suppression reaches approximately 70%.

Female-specific uses of finasteride

Finasteride is FDA-approved at 1 mg (Propecia brand, now generic) for androgenetic alopecia. Women with female pattern hair loss (FPHL) use the 1 mg dose off-label or, in some countries, through women-specific products. Higher doses (2.5 mg to 5 mg) are used off-label for hyperandrogenism in PCOS, hirsutism, and hormonal acne when other options have failed or are contraindicated.

The androgen-cardiovascular connection in women

Androgens are not simply male hormones. Elevated androgens in women, as seen in PCOS, are associated with dyslipidemia, insulin resistance, and increased cardiovascular risk. Women with PCOS are more likely to have elevated LDL-C and reduced HDL-C, which can make PCSK9 inhibition with evolocumab relevant if familial hypercholesterolemia co-exists. The two conditions can and do occur together, meaning some women may genuinely be on both drugs.

Pharmacokinetic Interaction Analysis: CYP, P-gp, and Protein Binding

The table below summarizes the key pharmacokinetic parameters relevant to an interaction assessment.

| Parameter | Evolocumab (Repatha) | Finasteride | |---|---|---| | Drug class | Monoclonal antibody (IgG2) | 5-AR inhibitor (small molecule) | | Primary elimination | Proteolytic catabolism | CYP3A4 hepatic metabolism | | CYP substrate | No | Yes (CYP3A4, minor CYP1A2) | | CYP inhibitor/inducer | No | No | | P-gp substrate | No | Weak | | Protein binding | N/A (catabolized) | ~90% plasma protein bound | | Half-life | ~11-17 days (subcutaneous) | ~5-6 hours (1 mg); ~6 hours (5 mg) | | Renal elimination | Negligible | ~39% unchanged in urine |

Because evolocumab has no CYP activity and no P-glycoprotein interaction, it cannot alter finasteride exposure through any known pharmacokinetic mechanism. The FDA drug interaction guidance for monoclonal antibodies confirms this class-level principle.

Could pharmacodynamic overlap exist?

Pharmacodynamic interactions occur when two drugs affect the same physiological endpoint, even without touching each other's metabolism. Evolocumab lowers LDL-C. Finasteride lowers DHT. These are different endpoints. No published mechanistic or clinical data suggest that lowering DHT alters PCSK9 expression or that blocking PCSK9 alters 5-AR activity. A 2019 analysis of androgen receptor signaling and hepatic lipid metabolism found no direct regulatory link between 5-AR inhibition and PCSK9 gene expression in human hepatocytes, though this remains an area of active investigation.

The combination does not carry a pharmacodynamic interaction warning in any major drug interaction database (Lexicomp, Micromedex, or the FDA label for either agent).

Life-Stage Considerations for Women on Both Drugs

Reproductive years (ages approximately 18-40)

This is the most complex life stage for finasteride. Finasteride is classified FDA Pregnancy Category X, meaning animal and human data confirm fetal harm and the risks outweigh any possible benefit in pregnancy. Specifically, finasteride inhibits DHT-dependent virilization of the external genitalia in male fetuses. A woman who becomes pregnant while taking finasteride risks bearing a male infant with ambiguous or feminized external genitalia (hypospadias and incomplete scrotal fusion).

If you are of reproductive age and a clinician prescribes finasteride for FPHL, PCOS-related hirsutism, or hormonal acne, you need reliable contraception for the entire duration of treatment and for at least one month after the last dose. Barrier methods alone are not considered sufficient; combined hormonal contraception, an intrauterine device, or an implant are preferred.

Evolocumab in the reproductive years carries a different profile. The FOURIER trial excluded pregnant and breastfeeding women, so direct evidence in this population is absent. Animal reproduction studies showed no teratogenicity, and the FDA label advises that evolocumab should be used in pregnancy only if the potential benefit justifies the potential risk.

Women with familial hypercholesterolemia (FH) who become pregnant face a particularly difficult trade-off. Statins must be stopped in pregnancy, but untreated FH carries significant cardiovascular risk. ACOG guidance on lipid management in pregnancy acknowledges that PCSK9 inhibitors lack sufficient pregnancy data and should be used only when the clinical situation is exceptional.

Perimenopause (approximately ages 45-55)

Cholesterol levels typically rise during perimenopause as estrogen, which upregulates hepatic LDL receptors, declines. Women who were previously at lipid targets may find LDL-C climbing even without dietary changes. If the rise is driven by heterozygous FH or established ASCVD, evolocumab becomes a more likely prescription. Finasteride may also remain relevant during perimenopause for women managing FPHL, which often worsens as estrogen levels fall and the relative androgen effect increases.

The combination in perimenopause carries the same absent pharmacokinetic interaction, but the cardiovascular context becomes more pressing. Perimenopause is when 10-year ASCVD risk begins to climb sharply for many women, and LDL management is a primary modifiable factor.

Post-menopause

Post-menopausal women are the most likely group to need evolocumab for cardiovascular risk reduction. Contraception concerns for finasteride are resolved, though some women continue finasteride for persistent FPHL, which affects roughly 40% of women by age 70. The absence of pregnancy risk in this group simplifies prescribing considerably.

Pregnancy and Lactation Safety: A Required Section

Finasteride

Pregnancy: Contraindicated. FDA Pregnancy Category X. Even handling crushed or broken finasteride tablets is cautioned against in pregnancy because of theoretical dermal absorption, though the clinical significance of topical absorption from intact skin contact is debated. The FDA label states unambiguously that finasteride is contraindicated in women who are or may become pregnant.

Lactation: No human lactation data exist. Because finasteride is lipophilic and has moderate protein binding (approximately 90%), transfer into breast milk is plausible. Given the theoretical risk to a breastfed male infant's androgen-dependent development, finasteride should not be used while breastfeeding. LactMed (NIH) lists finasteride as incompatible with breastfeeding.

Contraception requirement: Effective contraception is mandatory throughout finasteride use and for at least one month after stopping.

Evolocumab

Pregnancy: No adequate and well-controlled studies in pregnant women exist. Animal studies (rats, rabbits) at exposures exceeding the human therapeutic range showed no adverse developmental effects. The FDA label advises clinicians to consider the benefit-risk balance. For women with severe FH who have had prior ASCVD events, the benefit may outweigh the theoretical risk, but this decision requires specialist input.

Lactation: Human IgG antibodies are present in breast milk in small amounts. Evolocumab, as an IgG2 antibody, is likely to appear in breast milk at low levels. Oral bioavailability of large proteins in a nursing infant is expected to be negligible because gastric acid and intestinal proteases degrade them. The clinical risk to the infant is considered low, but no pharmacokinetic breast milk studies in humans are published. A clinician should weigh cardiovascular necessity against the absence of data.

Contraception requirement: No specific requirement, but pregnancy planning discussions should happen with any woman of reproductive age prescribed evolocumab for FH.

Who This Combination Is Right For (and Who Should Be Cautious)

Women for whom this combination is appropriate

• Post-menopausal women with established ASCVD or heterozygous FH who also have FPHL
• Peri-menopausal women with statin-refractory LDL elevation and concurrent androgenic alopecia, provided effective contraception is in place
• Women with PCOS and co-existing FH who are on finasteride for hyperandrogenism and need aggressive LDL-C reduction beyond what a statin provides

Women who need additional caution or specialist input

• Women of reproductive age on finasteride who are not using highly effective contraception. Adding evolocumab does not change the finasteride pregnancy risk, but the cardiovascular indication for evolocumab should prompt a full contraceptive review before prescribing.
• Women with severely elevated LDL-C during pregnancy. Neither drug is straightforwardly safe in pregnancy; a maternal-fetal medicine specialist and lipid specialist should co-manage.
• Women on combined hormonal contraceptives (CHC) for contraception while on finasteride. CHCs are CYP3A4 substrates, and some formulations may slightly alter finasteride exposure, though this effect is not considered clinically significant. Evolocumab does not change this picture.

Evidence Gaps: What We Don't Know

Women have been underrepresented in cardiovascular outcomes trials. In FOURIER, women made up only 24.6% of the enrolled population, meaning LDL-lowering effect estimates and cardiovascular event reduction data are primarily derived from male participants. Subgroup analyses suggest similar relative risk reduction in women, but absolute numbers are smaller and confidence intervals are wider.

For finasteride in women, most trial data come from small, short-duration studies of FPHL or PCOS, typically involving fewer than 200 participants and rarely lasting beyond 12 months. The longest head-to-head RCT of finasteride versus placebo for FPHL showed no significant difference at the 1 mg dose in post-menopausal women, though higher doses (2.5 mg to 5 mg) showed benefit in some series.

The direct combination of evolocumab and finasteride in women has never been studied in a clinical trial. There is no reason to expect harm based on pharmacology, but the honest answer is that the evidence is a single-arm extrapolation from mechanism, not from data.

As Dr. Elena Vasquez, MD, WomanRx editorial board reviewer, notes: "The absence of a pharmacokinetic interaction between evolocumab and finasteride is well-supported by mechanism, but clinicians and women need to keep both drugs' independent pregnancy contraindications clearly in view. The conversation about contraception can't be skipped just because one of the two agents looks cardiovascular on the surface."

Monitoring and Practical Guidance

After starting evolocumab

Check a fasting lipid panel 4 to 12 weeks after the first injection to confirm LDL-C response. The target for women with established ASCVD is generally LDL-C <70 mg/dL per 2018 AHA/ACC guidelines, with some high-risk patients now targeted at <55 mg/dL. No dose adjustment of finasteride is needed when evolocumab is added.

Injection site and adherence

Evolocumab is given as a 140 mg subcutaneous injection every two weeks, or 420 mg once monthly via an auto-injector. Injection site reactions occur in about 3% of patients. Because this is a biologic, consistent storage (refrigerated at 36°F to 46°F) matters. Women managing both FPHL and cardiovascular disease often deal with treatment fatigue; building the injection into an existing routine (such as a monthly telehealth check-in) improves persistence.

Finasteride monitoring

Liver function tests are not routinely required at standard doses, but women using higher off-label doses (5 mg) for PCOS-related hyperandrogenism should have baseline liver enzymes checked given that CYP3A4 hepatic metabolism is the primary elimination route. Serum DHT levels can confirm suppression if clinical response (reduction in hair shedding or hirsutism score) is unclear after six months.

Repatha Drug Interactions: The Broader Picture for Women

Because evolocumab bypasses CYP metabolism entirely, its drug interaction profile is nearly blank from a pharmacokinetic standpoint. The interactions that matter for women on Repatha are pharmacodynamic:

• Statins: Adding evolocumab to a statin is the standard approach for FH. Statins upregulate PCSK9 expression, which is why evolocumab's LDL-lowering effect is additive rather than redundant. In the LAPLACE-2 trial, evolocumab reduced LDL-C by 63-75% on top of high-intensity statins.
• Ezetimibe: Safe combination. Ezetimibe reduces intestinal cholesterol absorption through a separate mechanism (NPC1L1 inhibition).
• Hormonal contraceptives and hormone therapy: No pharmacokinetic interaction with evolocumab. Women on combined oral contraceptives or menopausal hormone therapy do not need dose adjustments of either agent.
• SGLT2 inhibitors or GLP-1 receptor agonists: No interaction. Women using cardiometabolic agents for PCOS or type 2 diabetes can use evolocumab without adjustment.